Vorapaxar is a new anti-platelet drug that is part of the PAR-1 antagonist family, a new class of anti-platelet drug. It functions by inhibiting thrombin-related platelet aggregation. This mechanism works by a different pathway than other anti-platelet medications such as P2Y12 inhibitors. Unlike many other medication, vorapaxar does not affect ADP-mediated platelet aggregation, coagulation parameters, or bleeding time.
Vorapaxar is a new anti-platelet drug that is part of the PAR-1 antagonist family, a new class of anti-platelet drug. It functions by inhibiting thrombin-related platelet aggregation. This mechanism works by a different pathway than other anti-platelet medications such as P2Y12 inhibitors. Unlike many other medication, vorapaxar does not affect ADP-mediated platelet aggregation, coagulation parameters, or bleeding time.
![(2R,3S)-2-[(1R)-1-[3,5-Bis(trifluoromethyl)phenyl)ethoxy]-3-(4-fluorophenyl)morpholine](https://cpimg.tistatic.com/01586145/s/4/-2R-3S-2-1R-1-3-5-Bis-trifluoromethyl-phenyl-ethoxy-3-4-fluorophenyl-morpholine.jpg)
![2-(Methylsulfonyl)-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole benzenesulfonate](https://cpimg.tistatic.com/03138848/s/4/-2-Methylsulfonyl-2-4-5-6-tetrahydropyrrolo-3-4-c-pyrazole-benzenesulfonate.jpg)
Suite B-10, Chuansha Road 6999#, Shanghai, Shanghai, 201203, China
Phone :86-21-50790412/31268550